Sector News

Sanofi signs $1.5bn-plus cancer immunotherapy deal with BioNTech

November 5, 2015
Life sciences

Sanofi is linking arms with BioNTech under multiyear exclusive collaboration and license agreement targeting the discovery and development of up to five new cancer immunotherapies containing a mix of messenger RNAs, that could bring more than $1.5 billion to the latter’s books.

Sanofi is paying BioNTech $60 million in upfront and near-term milestone payments for rights to the candidates based on the latter’s technology, but the firm could receive over $300 million more in development, regulatory and commercial milestones and other payments, as well as sales-based royalties, for each product.

Under the terms of the deal, BioNTech also holds the option to co-develop and co-commercialise two of the five mRNA therapeutics products with Sanofi in the European Union and the US.

“The collaboration with Sanofi is groundbreaking: through using our broad suite of mRNA technologies and extensive tumor immunology understanding, it will allow us to develop a completely new class of cancer immune-therapeutics with Sanofi, which we believe will have a profound and deep impact on the treatment of cancer,” said BioNTech chief executive Ugur Sahin, commenting on the move.

Source: Pharma Times

comments closed

Related News

October 2, 2022

GSK names Julie Brown, a 25-year AstraZeneca veteran, its first woman CFO

Life sciences

Five years ago, GSK made headlines when it hired Emma Walmsley to become the first woman to run a major pharmaceutical company. Now the Big Pharma has brought in another woman to control the company’s finances. Julie Brown will be GSK’s next chief financial officer. Brown, currently the chief operating and financial officer at fashion and beauty brand Burberry Group, is set to replace Iain Mackay.

October 2, 2022

Moderna creates new launch preparation role, poaches Novartis exec as manufacturing lead

Life sciences

Moderna created a new role responsible for “building out the company’s organization to support its growing pipeline.” Starting first thing 2023, Juan Andres, Moderna’s manufacturing head, will step into this new role under the title president of strategic partnerships and enterprise expansion, the company said Thursday.

October 2, 2022

Torrent Pharma to acquire Curatio for $245.16m

Life sciences

The latest takeover is anticipated to boost the presence of Torrent in the dermatology segment. Indian company Torrent Pharmaceuticals has signed a definitive agreement for the complete acquisition of Curatio Healthcare for $245.16m (Rs20bn).